Literature DB >> 23162807

Dual, enzymatic and non-enzymatic, function of ecto-5'-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells.

Rafal Sadej1, Andrzej C Skladanowski.   

Abstract

Ecto-5'-nucleotidase (eN, CD73) mediates extracellular adenosine production from 5'-AMP. Non-enzymatic functions of eN have also been reported. The aim of the study was to investigate the role of ecto-5'-nucleotidase in aggressive melanoma behaviour. Analysis of the involvement of eN in adhesion, migration and invasion revealed eN functions unknown to date. We found that following eN blockade by concanavalin A, the strength of adhesion to different ECM proteins was not altered, but at the same time the invasion ability of the cells was decreased. On the other hand, knocking down eN in melanoma cells did not influence cell invasion but abolished their migration on tenascin C (TnC). Ecto-5'-nucleotidase seems to fulfil a more distinct role as a receptor than as an enzyme in the cell interaction and mobility on TnC. Ecto-5'-nucleotidase activates also focal adhesion kinase and enhances the formation of complexes upon cell adhesion to TnC. All these observations prove that an eN-TnC complex is involved in cell migration and invasion and thus in the regulation of melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23162807

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  35 in total

1.  Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Authors:  Dipti Vijayan; Deborah S Barkauskas; Kimberley Stannard; Erin Sult; Rebecca Buonpane; Kazuyoshi Takeda; Michele W L Teng; Kris Sachsenmeier; Carl Hay; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

Review 2.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

3.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

4.  Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.

Authors:  Anna M Nguyen; Jianhong Zhou; Brihget Sicairos; Sangeetha Sonney; Yuchun Du
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

Review 5.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Extracellular ATP Selectively Upregulates Ecto-Nucleoside Triphosphate Diphosphohydrolase 2 and Ecto-5'-Nucleotidase by Rat Cortical Astrocytes In Vitro.

Authors:  Dusica Brisevac; Marija Adzic; Danijela Laketa; Ana Parabucki; Milena Milosevic; Irena Lavrnja; Ivana Bjelobaba; Jean Sévigny; Markus Kipp; Nadezda Nedeljkovic
Journal:  J Mol Neurosci       Date:  2015-06-17       Impact factor: 3.444

7.  CD73 promotes cervical cancer growth via EGFR/AKT1 pathway.

Authors:  Chong Liu; Zhao-Wei Gao; Xi Wang; Fang Lin; Hui-Zhong Zhang; Ke Dong
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 8.  The adenosine pathway in immuno-oncology.

Authors:  Bertrand Allard; David Allard; Laurence Buisseret; John Stagg
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

9.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

10.  NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein.

Authors:  Michel Fausther; Elise G Lavoie; Jessica R Goree; Giulia Baldini; Jonathan A Dranoff
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.